Cost-effectiveness of prostate cancer chemoprevention among high-risk men

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 10, Issue 5, 2010, Pages 505-508

  Zeliadt, Steven B ^a   Ramsey, Scott D ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

5 reductase inhibitor; benign prostatatic hyperplasia; chemoprevention; cost effectiveness; Markov model; prostate cancer

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DUTASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

CANCER GRADING; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEART FAILURE; HIGH RISK PATIENT; HUMAN; IMPOTENCE; INTENSITY MODULATED RADIATION THERAPY; LIBIDO DISORDER; NOTE; ONSET AGE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RECURRENCE RISK; RISK FACTOR; TRANSURETHRAL RESECTION;

EID: 77958195523     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.10.63     Document Type: Note

References (16)

1. Earnshaw SR, McDade CL, Black LK, Bell CF, Kattan M W. Cost effectiveness of 5-α reductase inhibitors for the prevention of prostate cancer in multiple patient populations. Pharmacoeconomics 28(6), 489-505 (2010).
2. Stephenson AJ, Scardino PT, Eastham JA et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J. Clin. Oncol. 23(28), 7005-7012 (2005).
3. Nam RK, Toi A, Klotz LH et al. Assessing individual risk for prostate cancer. J. Clin. Oncol. 25(24), 3582-3588 (2007).
4. Andriole GL, Bostwick DG, Brawley OW et al. Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 362(13), 1192-1202 (2010). •• The 4-year results of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, which focused on chemoprevention among men with elevated prostate-specific antigen (PSA) and a prior negative biopsy
5. Lepor H, Williford WO, Barry MJ et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N. Engl. J. Med. 335(8), 533-539 (1996).
6. Kirby RS, Roehrborn C, Boyle P et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 61(1), 119-126 (2003).
7. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. 349(25), 2387-2398 (2003).
8. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349(3), 215-224 (2003).
9. Kramer BS, Hagerty KL, Justman S et al. Use of 5-α-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J. Clin. Oncol. 27(9), 1502-1516 (2009). •• Guidelines and recommendations for discussing 5-a reductase inhibitor (5ARI) chemoprevention with men with asymptomatic, low risk of developing prostate cancer with PSA less than 3.0 ng/ml.
10. Redman MW, Tangen CM, Goodman PJ et al. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev. Res. (Phila. PA) 1(3), 174-181 (2008).
11. Pinsky P, Parnes H, Ford L. Estimating rates of true high-grade disease in the Prostate Cancer Prevention Trial. Cancer Prev. Res. (Phila. PA) 1(3), 182-186 (2008). • Detailed examination of high-grade outcomes using surgical specimens among patients in the placebo and treatment arms of the Prostate Cancer Prevention Trial who went on to have radical prostatectomy.
12. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293(17), 2095-2101 (2005).
13. Zeliadt SB, Etzioni RD, Penson DF, Thompson IM, Ramsey SD. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am. J. Med. 118(8), 850-857 (2005). • Prior study of cost-effectiveness of chemoprevention in the general population focusing on long-term outcomes associated with low-and high-grade disease.
14. Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer 112(5), 1058-1065 (2008). • Prior study of cost-effectiveness of chemoprevention in the general population focusing on cost of treatment.
15. Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. The cost of prostate cancer chemoprevention: a decision analysis model. Cancer Epidemiol. Biomarkers Prev. 15(8), 1485-1489 (2006).
16. Sanda MG, Dunn RL, Michalski J et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl. J. Med. 358(12), 1250-1261 (2008).